Biofrontera Equity Warrants 27th Oct 2026 BFRIW:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
0.0599quote price arrow down-0.0001 (-0.1667%)
Volume
17,010
52 week range
0.00 - 0.37
Loading...
  • Open0.0595
  • Day High0.06
  • Day Low0.0595
  • Prev Close0.06
  • 52 Week High0.37
  • 52 Week High Date07/03/23
  • 52 Week Low0.00
  • 52 Week Low Date12/19/23

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.0595
  • Day High0.06
  • Day Low0.0595
  • Prev Close0.06
  • 52 Week High0.37
  • 52 Week High Date07/03/23
  • 52 Week Low0.00
  • 52 Week Low Date12/19/23
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Biofrontera Equity Warrants 27th Oct 2026

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription...
Hermann Luebbert Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Eugene Frederick Leffler III
Chief Financial Officer
Address
120 Presidential Way,, Suite 330
Woburn, MA
01801
United States